| 摘要 |
The present disclosure is directed to compositions and methods for detecting signs of telomere dysfunction as diagnostic indicators of metastatic disease. More particularly, diagnostic reagents and procedures are provided for analyzing samples to detect the presence of telomere fusions as an early diagnostic test for cancerous or pre-cancerous cells. |
